All In Biotech

Drug Trial Radar · NCT00843921

N-Carbamylglutamate (Carbaglu) In The Treatment Of Hyperammonemia

Last checked: Nov 20, 2026Latest source record: Feb 17, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

52

Actual

Start

Aug 2008

Primary completion

Apr 25, 2018

Study completion Jun 30, 2020

Sponsor

Lead sponsor
Mendel TuchmanAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
First posted
Feb 13, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 1 day, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is based on the hypothesis that a new drug N-carbamylglutamate (Carbaglu®) will enhance the ability of the liver to dispose of toxic ammonia which accumulates in several metabolic diseases including urea cycle disorders and organic acid disorders.

Conditions

  • Inborn Errors of Metabolism

Interventions

  • N-carbamylglutamateDrug

    100 mg/kg/day or 2.2 g/M2/day in 3-4 divided doses for 3 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of ureagenesis as determined by 13C enrichment of ureaTime frame: 3 days of treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Childrens Research Institute

    Washington D.C., District of Columbia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.